 Hydroxymethylglutaryl-CoA Reductase Inhibitors
"Hydroxymethylglutaryl-CoA Reductase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit HMG-CoA reductases. They have been shown to directly lower cholesterol synthesis.
| Descriptor ID |
D019161
|
| MeSH Number(s) |
D27.505.519.186.071.202.370 D27.505.519.389.370 D27.505.954.557.500.202.370
|
| Concept/Terms |
Hydroxymethylglutaryl-CoA Reductase Inhibitors- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Hydroxymethylglutaryl CoA Reductase Inhibitors
- Inhibitors, Hydroxymethylglutaryl-CoA Reductase
- Reductase Inhibitors, Hydroxymethylglutaryl-CoA
- Statins, HMG-CoA
- HMG-CoA Statins
- Statins, HMG CoA
- Inhibitors, Hydroxymethylglutaryl-CoA
- Hydroxymethylglutaryl-CoA Inhibitors
- Inhibitors, Hydroxymethylglutaryl CoA
- Inhibitors, Hydroxymethylglutaryl-Coenzyme A
- Hydroxymethylglutaryl-Coenzyme A Inhibitors
- Inhibitors, Hydroxymethylglutaryl Coenzyme A
- HMG-CoA Reductase Inhibitors
- HMG CoA Reductase Inhibitors
- Reductase Inhibitors, HMG-CoA
- Inhibitors, HMG-CoA Reductase
- Inhibitors, HMG CoA Reductase
|
Below are MeSH descriptors whose meaning is more general than "Hydroxymethylglutaryl-CoA Reductase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Hydroxymethylglutaryl-CoA Reductase Inhibitors".
This graph shows the total number of publications written about "Hydroxymethylglutaryl-CoA Reductase Inhibitors" by people in this website by year, and whether "Hydroxymethylglutaryl-CoA Reductase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1987 | 0 | 1 | 1 | | 1988 | 0 | 1 | 1 | | 1989 | 0 | 1 | 1 | | 1990 | 1 | 0 | 1 | | 1991 | 1 | 0 | 1 | | 1992 | 1 | 0 | 1 | | 1994 | 0 | 3 | 3 | | 1995 | 2 | 0 | 2 | | 1996 | 2 | 0 | 2 | | 1997 | 3 | 0 | 3 | | 1998 | 7 | 1 | 8 | | 1999 | 4 | 0 | 4 | | 2000 | 2 | 3 | 5 | | 2001 | 6 | 2 | 8 | | 2002 | 11 | 5 | 16 | | 2003 | 20 | 6 | 26 | | 2004 | 19 | 4 | 23 | | 2005 | 18 | 2 | 20 | | 2006 | 15 | 4 | 19 | | 2007 | 22 | 3 | 25 | | 2008 | 23 | 13 | 36 | | 2009 | 15 | 5 | 20 | | 2010 | 11 | 3 | 14 | | 2011 | 15 | 2 | 17 | | 2012 | 15 | 6 | 21 | | 2013 | 10 | 3 | 13 | | 2014 | 12 | 10 | 22 | | 2015 | 10 | 2 | 12 | | 2016 | 9 | 5 | 14 | | 2017 | 13 | 5 | 18 | | 2018 | 5 | 3 | 8 | | 2019 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Hydroxymethylglutaryl-CoA Reductase Inhibitors" by people in Profiles.
-
Shenkar R, Peiper A, Pardo H, Moore T, Lightle R, Girard R, Hobson N, Polster SP, Koskimäki J, Zhang D, Lyne SB, Cao Y, Chaudagar K, Saadat L, Gallione C, Pytel P, Liao JK, Marchuk D, Awad IA. Rho Kinase Inhibition Blunts Lesion Development and Hemorrhage in Murine Models of Aggressive Pdcd10/Ccm3 Disease. Stroke. 2019 03; 50(3):738-744.
-
Paul S, Davis AM. Diagnosis and Management of Nonalcoholic Fatty Liver Disease. JAMA. 2018 Dec 18; 320(23):2474-2475.
-
Wei WQ, Li X, Feng Q, Kubo M, Kullo IJ, Peissig PL, Karlson EW, Jarvik GP, Lee MTM, Shang N, Larson EA, Edwards T, Shaffer CM, Mosley JD, Maeda S, Horikoshi M, Ritchie M, Williams MS, Larson EB, Crosslin DR, Bland ST, Pacheco JA, Rasmussen-Torvik LJ, Cronkite D, Hripcsak G, Cox NJ, Wilke RA, Stein CM, Rotter JI, Momozawa Y, Roden DM, Krauss RM, Denny JC. LPA Variants Are Associated With Residual Cardiovascular Risk in Patients Receiving Statins. Circulation. 2018 10 23; 138(17):1839-1849.
-
Nicholls SJ, Lincoff AM, Bash D, Ballantyne CM, Barter PJ, Davidson MH, Kastelein JJP, Koenig W, McGuire DK, Mozaffarian D, Pedersen TR, Ridker PM, Ray K, Karlson BW, Lundström T, Wolski K, Nissen SE. Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial. Clin Cardiol. 2018 Oct; 41(10):1281-1288.
-
Cho L, Dent R, Stroes ESG, Stein EA, Sullivan D, Ruzza A, Flower A, Somaratne R, Rosenson RS. Persistent Safety and Efficacy of Evolocumab in Patients with Statin Intolerance: a Subset Analysis of the OSLER Open-Label Extension Studies. Cardiovasc Drugs Ther. 2018 08; 32(4):365-372.
-
Mach F, Ray KK, Wiklund O, Corsini A, Catapano AL, Bruckert E, De Backer G, Hegele RA, Hovingh GK, Jacobson TA, Krauss RM, Laufs U, Leiter LA, März W, Nordestgaard BG, Raal FJ, Roden M, Santos RD, Stein EA, Stroes ES, Thompson PD, Tokgözoglu L, Vladutiu GD, Gencer B, Stock JK, Ginsberg HN, Chapman MJ. Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. Eur Heart J. 2018 07 14; 39(27):2526-2539.
-
Davidson MH. Triglyceride-rich lipoprotein cholesterol (TRL-C): the ugly stepsister of LDL-C. Eur Heart J. 2018 02 14; 39(7):620-622.
-
McCullough PA, Ballantyne CM, Sanganalmath SK, Langslet G, Baum SJ, Shah PK, Koren A, Mandel J, Davidson MH. Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials). Am J Cardiol. 2018 04 15; 121(8):940-948.
-
Robinson JG, Davidson MH. Can We Cure Atherosclerosis? Rev Cardiovasc Med. 2018; 19(S1):S20-S24.
-
Ganz P, Amarenco P, Goldstein LB, Sillesen H, Bao W, Preston GM, Welch KMA. Association of Osteopontin, Neopterin, and Myeloperoxidase With Stroke Risk in Patients With Prior Stroke or Transient Ischemic Attacks: Results of an Analysis of 13 Biomarkers From the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trial. Stroke. 2017 12; 48(12):3223-3231.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|